Background:

XLR11 N-(4-hydroxypentyl) metabolite-d₅(CRM) is intended for use as an internal standard for the quantification of XLR11 N-(4-hydroxypentyl) metabolite by GC-or LC-mass spectrometry. XLR11 is a synthetic cannabinoid (CB) featuring a tetramethylcyclopropyl group, which reportedly confers selectivity for the peripheral CB₂receptor over the central CB₁receptor.¹XLR11 also has an N-(5-fluoropentyl) chain, which increases binding to both CB receptors.²XLR11 N-(4-hydroxypentyl) metabolite is an expected phase 1 metabolite of XLR11, based on the known metabolism of similar compounds.^3,4The physiological properties of this compound have not been evaluated. This product is intended for forensic and research applications.

1.Frost, J.M., Dart, M.J., Tietje, K.R., et al.Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activityJ. Med. Chem.53(1)295-315(2010) 2.Makriyannis, A., and Deng, H.Cannabimimetic indole derivativesPCT/US00/28832(2001) 3.Zhang, Q., Ma, P., Cole, R.B., et al.Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MSAnalytical and Bioanalytical Chemistry3861345-1355(2006) 4.Wintermeyer, A., MÖller, I., Thevis, M., et al.In vitro phase I metabolism of the synthetic cannabimimetic JWH-018Anal. Bioanal. Chem.398(5)2141-2153(2010)